Edward J. Fudman

Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein et al. · Arthritis & Rheumatism · 2008 · 203 citations

Dermatomyositis without creatine kinase elevation. A poor prognostic sign

Edward J. Fudman, Thomas J. Schnitzer · The American Journal of Medicine · 1986 · 157 citations

Rheumatology, Autoimmune Disease, Poor Prognostic Sign +6

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis

Robert F. Willkens, Murray B. Urowitz, Donald M. Stablein et al. · Arthritis & Rheumatism · 1992 · 118 citations

Rheumatoid Disorder, Rheumatology, Mtx Therapy +14

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

Philip J. Mease, Nathan Wei, Edward J. Fudman et al. · The Journal of Rheumatology · 2009 · 109 citations · Full text

Demonstration of a chemotactic factor receptor on macrophages.

Ralph Snyderman, Edward J. Fudman · The Journal of Immunology · 1980 · 102 citations

Inflammation, Macrophage Biology, Chemotactic Factor Receptor +14